India is the third-largest producer of drugs and pharmaceuticals in the world by volume and supplies roughly 20% of global generic medicine exports, but that scale rests on manufacturing and process chemistry rather than on original discovery. Very little of the industry's revenue goes into research on new chemical entities, new biological entities or novel devices, so high-value patented products and advanced medical devices are still largely imported. PRIP, approved in 2023 with a Rs 5,000 crore outlay running from 2023-24 to 2027-28, is the Department of Pharmaceuticals' answer: build the research infrastructure the country lacks through Centres of Excellence at the seven NIPERs, and then co-fund industry, MSMEs and startups so that early laboratory ideas can survive the long, expensive middle stretch before commercialisation. The mentorship arms - MedTech Mitra for device innovators and Patent Mitra for intellectual property - exist because the usual failure point for Indian pharma research is not the idea but regulatory navigation and IP.

A second call matters more than it sounds, because it shows the scheme is actually disbursing rather than sitting on paper - and the design has been sharpened. Splitting applications into an early-stage track for TRL 1-3 startups and a later-stage track for TRL 4-6 industry projects recognises that these are different funding problems: a startup needs small, fast money to prove a concept, while a company crossing into clinical or regulatory stages needs large capital with skin in the game, which is why the later-stage grant is capped at 35% of approved cost and the applicant co-funds the rest. Barring resubmission of first-round projects prevents the same proposals recycling through successive calls. For exam purposes, PRIP is the cleanest example of India trying to move from a volume-based 'pharmacy of the world' position built on generics to a value-based one built on patented molecules, devices and biosimilars.